James Aloysius Brady
CIK 1916987 · last filed 2026-06-05
James Aloysius Brady is a corporate insider who has filed 10 SEC Form 4 insider transactions across 2 companies since 2022. The most recent filing, for XERS, was dated Jun 5, 2026. Across all open-market trades the lifetime net is −$70.9K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
XERS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3 MORE LONDON RIVERSIDE
LONDON, X0 SE1 2RE
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XERS | Director | 113,359 | $10.31 | $1.17M | -$60.0K | 3 | 2026-06-05 |
| Verona Pharma plc (VRNA) Delisted | Director | 0 | $106.91 | $0 | -$10.8K | 6 | 2025-10-08 |
Recent Filings
10 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-05 | XERS | Grant (A) | +24,193 | $0 | EDGAR |
| 2026-04-01 | XERS | Sell (S) | −10,834 | -$60.0K | EDGAR |
| 2026-03-30 | XERS | Notice (144) | −10,834 | -$58.5K | EDGAR |
| 2025-10-08 | Verona Pharma plc (VRNA) Delisted | Mixed | −23,176 | $0 | EDGAR |
| 2025-08-05 | Verona Pharma plc (VRNA) Delisted | Mixed | +23,176 | -$10.8K | EDGAR |
| 2025-04-29 | Verona Pharma plc (VRNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-28 | XERS | Grant (A) | +100,000 | $0 | EDGAR |
| 2024-04-30 | Verona Pharma plc (VRNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-04-28 | Verona Pharma plc (VRNA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-16 | Verona Pharma plc (VRNA) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.